Making sense of big data in health research: Towards an EU action plan. by Auffray, Charles et al.
Auffray et al. Genome Medicine  (2016) 8:71 
DOI 10.1186/s13073-016-0323-yOPINION Open AccessMaking sense of big data in health research:
Towards an EU action plan
Charles Auffray1,2*, Rudi Balling3*, Inês Barroso4, László Bencze5, Mikael Benson6, Jay Bergeron7,
Enrique Bernal-Delgado8, Niklas Blomberg9, Christoph Bock10,11,12, Ana Conesa13,14, Susanna Del Signore15,
Christophe Delogne16, Peter Devilee17, Alberto Di Meglio18, Marinus Eijkemans19, Paul Flicek20, Norbert Graf21,
Vera Grimm22, Henk-Jan Guchelaar23, Yi-Ke Guo24, Ivo Glynne Gut25, Allan Hanbury26, Shahid Hanif27,
Ralf-Dieter Hilgers28, Ángel Honrado29, D. Rod Hose30, Jeanine Houwing-Duistermaat31, Tim Hubbard32,33,
Sophie Helen Janacek20, Haralampos Karanikas34, Tim Kievits35, Manfred Kohler36, Andreas Kremer37,
Jerry Lanfear38, Thomas Lengauer12, Edith Maes39, Theo Meert40, Werner Müller41, Dörthe Nickel42, Peter Oledzki43,
Bertrand Pedersen44, Milan Petkovic45, Konstantinos Pliakos46, Magnus Rattray41, Josep Redón i Màs47,
Reinhard Schneider3, Thierry Sengstag48, Xavier Serra-Picamal49, Wouter Spek50, Lea A. I. Vaas36,
Okker van Batenburg50, Marc Vandelaer51, Peter Varnai52, Pablo Villoslada53, Juan Antonio Vizcaíno20,
John Peter Mary Wubbe54 and Gianluigi Zanetti55,56Abstract
Medicine and healthcare are undergoing profound changes. Whole-genome sequencing and high-resolution
imaging technologies are key drivers of this rapid and crucial transformation. Technological innovation combined
with automation and miniaturization has triggered an explosion in data production that will soon reach exabyte
proportions. How are we going to deal with this exponential increase in data production? The potential of “big
data” for improving health is enormous but, at the same time, we face a wide range of challenges to overcome
urgently. Europe is very proud of its cultural diversity; however, exploitation of the data made available through
advances in genomic medicine, imaging, and a wide range of mobile health applications or connected devices is
hampered by numerous historical, technical, legal, and political barriers. European health systems and databases are
diverse and fragmented. There is a lack of harmonization of data formats, processing, analysis, and data transfer,
which leads to incompatibilities and lost opportunities. Legal frameworks for data sharing are evolving. Clinicians,
researchers, and citizens need improved methods, tools, and training to generate, analyze, and query data effectively.
Addressing these barriers will contribute to creating the European Single Market for health, which will improve health
and healthcare for all Europeans.European healthcare systems and the potential
for big data
Medicine has traditionally been a science of observation
and experience. For thousands of years, clinicians have
integrated the knowledge of preceding generations with
their own life-long experiences to treat patients accord-
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The digitalization of medicine allows the comparison of
disease progression or treatment responses from patients
worldwide. Whole-genome sequencing allows searching
and comparing one’s own genome to millions and soon
billions of other human genomes. Eventually, the entire
world population could be used as a reference popula-
tion in order to link genome information with many
other types of physiological, clinical, environmental, and
lifestyle data. For many, this is a vision full of opportun-
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acy and autonomy.
The quality of conclusions on the etiology of diseases
follows a law of large numbers. Cross-sectional cohort
studies of 30,000 to 50,000 or more cases are required to
separate the signal from noise and to detect genomic
regions associated with a given trait in which disease-
related genes or susceptibility factors are located [1, 2].
Whole-genome sequencing studies often identify only a
few genomic regions that contain elements with large ef-
fects on the penetrance or expressivity of gene products
but hundreds of genomic regions that have small effects
and are highly dependent on genetic background, envir-
onmental factors, or social and lifestyle determinants [3].
There is also a need to study disease pathogenesis on
genome, epigenome, transcriptome, proteome, and me-
tabolome levels and combine these dimensions through
multi-omics research. Furthermore, individual variation
responsible for normal and disease phenotypes is high as
a result of somatic mutations or variation in transcrip-
tion, splicing, or allele-specific gene expression between
individuals [4–6].
Vast amounts of temporal and spatial parameter data
are now available. But what are we going to do with the
data? It takes hard work to condense useful information
from big data and turn this information into knowledge
and action. The challenge will be to make a smart choice
between situations when less is more versus less is less
but also when more is more versus more is less.
Here, we briefly describe the key challenges that result
from making sense out of big data in health and using
these data for the benefit of the patient and the healthcare
system. We also highlight key technical, legal, and ethical
issues that we face to develop evidence-based personalized
medicine. Finally, we put forward five recommendations
for the European Union (EU) and member states’ policy
makers to serve as a framework for an EU action plan that
could help to reach this ambitious goal.
Making sense of big data in health research
On 30 October 2015, the Health Directorate of the
Directorate-General for Research and Innovation at the
European Commission (EC), the executive body of the
EU, organized in Luxembourg a workshop entitled “Big
data in health research: an EU action plan” [7]. The aim
of the workshop was to ask stakeholders in the “big data
revolution” for their input on how European funding for
health research should take into account the opportun-
ities, limitations, and concerns of the anticipated develop-
ments in health and healthcare. Participants included
bioinformaticians, computational biologists, genome sci-
entists, drug developers, biobanking experts, experimental
biologists, biostatisticians, information and communica-
tion technology (ICT) experts, public health researchers,clinicians, public policy experts, representatives of health
services, patient advocacy groups, the pharmaceutical in-
dustry, and ICT companies.
What do we mean by “big data”?
“Big data” has a wide range of definitions in health re-
search [8, 9] and to create a single definition for all uses
(“one size fits all” approach) may be too abstract to be
useful. However, a workable definition of what big data
means for health research or at least a consensus of what
this term means was proposed during the workshop in
Luxembourg. “Big data in health” encompasses high
volume, high diversity biological, clinical, environmen-
tal, and lifestyle information collected from single indi-
viduals to large cohorts, in relation to their health and
wellness status, at one or several time points. Big data
can only be dealt with by adopting a strong governance
model and best practices of new technologies, e.g., in
large-scale data production compliant with community-
based quality standards, coupled with interoperable data
storage, data integration, and advanced analytics solutions
[10]. Another goal of the workshop was to develop an EU
action plan for research funders towards the integration of
big data into policy development, biomedical research,
and clinical practice in health and wellness management.
Big data comes from a variety of sources, such as clinical
trials, electronic health records (EHRs), patient registries
and databases, multidimensional data from genomic, epi-
genomic, transcriptomic, proteomic, metabolomic, and
microbiomic measurements, and medical imaging. More
recently, data are being integrated from social media, so-
cioeconomic or behavioral indicators, occupational infor-
mation, mobile applications, or environmental monitoring
[11]. Big data comes in a wide range of formats. Data
streams have to be assessed and interpreted in a timely
manner to benefit patients affected by diseases and to help
citizens remain in good health [8, 12].
Importance of patient registries
Patient registries have for decades served as a key tool for
assessing clinical outcome and clinical and health technol-
ogy performance [13–15]. Rare disease registries pool data
to achieve a sufficient sample size for epidemiological and/
or clinical research [16, 17]. The European Organization for
Research and Treatment of Cancer (EORTC) [18] opened a
prospective registry for patients with melanoma in June
2015 [19]. The European Network of Cancer Registries
(ENCR) [20], established within the framework of the
Europe Against Cancer Programme of the EC, pro-
motes collaboration between cancer registries, defines
data collection standards, provides training for cancer
registry personnel, and regularly disseminates informa-
tion on incidence and mortality from cancer in the
European Union and other European countries.
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search and public health improvements in the EU,
owing to the large volume of patients in each registry
and the variety of quality medical information related
to each patient. Patient registries are increasingly im-
portant to monitor patients’ treatments and for safety
assessment and the identification of trends in transla-
tional medicine (e.g., registry-based clinical trials, per-
sonalized medicine) [21].
Patient registries allow informed policy decisions at the
local, regional, national, and, in some cases, the inter-
national level. As a result, hundreds of registries have been
set up that range from national to international rare disease
initiatives, coupling clinical and genetic data and biobanks.
However, for various reasons, including data protection
and the fragmentation of regulatory frameworks, the com-
bination of these disparate information sources to guide
health research and decision-making in the clinic has so far
lagged behind the use of large-scale, big data collections in
other sectors. Other disciplines, such as electronic and
mechanical engineering, and whole industries, such as
building airplanes, weather forecasting, or robotics, have
demonstrated computational modeling and simulation as
an essential component that is based on data sharing and
their experience could help overcome the barriers experi-
enced in health research [22–24].
The potential benefits of big data for healthcare
Big data in health can be used to improve the efficiency
and effectiveness of prediction and prevention strategies
or of medical interventions, health services, and health
policies [25–27]. Access to well-curated and high quality
health-related data will likely have a number of benefits
in a diverse range of situations. In clinical practice, these
data will improve outcomes for individual patients
through personalization of predictions, earlier diagnosis,
better treatments, and improved decision support for
clinicians in cyclic processes. (Cyclic processes are usu-
ally composed of the definition of policy/decision op-
tions, the selection of the best alternative, and the
subsequent implementation and validation of this op-
tion. Integrating feedback from a continuous evaluation
on the process completes this cycle [28].) These im-
provements should eventually lead to lowered costs for
the healthcare system.
Likewise, the integration of fragmented information sys-
tems into the clinical life cycle will allow the discovery of
medically relevant associations, early signals, or changed
disease trajectories and should, therefore, enable better
patient management strategies and improved quality and
safety of care. For clinical trials, more expansive, inter-
operable health records should make it much easier to
find suitable participants and to design and assess the
feasibility of new studies [29, 30]. Moreover, bettermanagement of big data would enable a more systematic
identification of drug safety signals, such as earlier detec-
tion of adverse drug reactions [31], while allowing person-
alized medicine analyses via appropriate patient and/or
population stratification methodologies. This in turn
should lead to improved treatment responses for biologic-
ally or clinically defined patient subgroups, which will also
avoid unnecessary rejection of potent drugs and devices.
As a result, patient communities will benefit and the un-
sustainable trend of escalating costs in hospital and com-
munity care management as well as diagnostic and drug
development costs by the biopharma industries will stop
or slow down. Health economy specialists need to provide
suitable metrics to monitor key performance indicators of
success in big data pilot projects. Such metrics might in-
clude the change in response rates in stratified patient
subpopulations or the number of adverse drug reactions
after systems medicine-based companion diagnostics.
Big data also has many potential benefits for transla-
tional research into health and well-being. Integrated
data sets should improve models of common disease to
better understand the progression of rare diseases [32].
They may also enable the detection of population-level
effects, such as the off-target and adverse effects of
drugs or the occurrence of co-morbidity [33].
Biomarkers constitute a key building block of precision
medicine, yet the development and clinical validation of
new biomarkers is a lengthy process and relatively few
such markers have yet reached routine clinical practice
[34, 35]. However, a sizeable number of biomarkers are
now widely used in routine clinical diagnostics, which
include—but are not limited to—targeted cancer therapy
[36–39]. Multidimensional signatures that take into ac-
count a wealth of prior information, both from the pa-
tient’s previous life history and state-of-the-art information
from the literature and relevant databases, will hopefully
deliver a much higher predictive power than the single
biomarkers used today. There is also potential for re-
search on the impact of healthcare interventions and
monitoring trends in infectious diseases to inform pub-
lic health policies [40].
Finally, there is an opportunity to engage with the indi-
vidual patient more closely and import data from mobile
health applications or connected devices. This interaction
with the patient will result in the collection of more de-
tailed clinical, environmental, and lifestyle information,
such as heart frequency and body temperature, physical
activity and nutrition habits, and sleep and stress manage-
ment, which will prevent risk exposure and disease onset
[41]. Personal monitoring over time should aid the early
detection of deviations from a healthy state and trajector-
ies should lead to actionable recommendations, making it
possible for individuals to maintain themselves in good
health [12].
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data in healthcare
To refine the recommendations for an EU action plan,
we identified the main challenges that exist for the use
of big data in healthcare research and in the clinic. The
challenges have been reported elsewhere [42, 43] and in-
clude clinical, technical, legal, and cultural hurdles.
These challenges vary depending on whether the data
are preclinical based on cellular or animal models or
from patients in clinical settings, on the intended type of
analysis and interpretation, on cross-cultural aspects of
privacy, and on ethical and legal considerations. We are
on the cusp of having access to vast personal data—for
example, on physiological, behavioral, molecular, clinical,
environmental exposure, medical imaging, disease man-
agement, medication prescription history, nutrition, or
exercise parameters—that could potentially be used to
track the health of individuals and populations in con-
siderably more detail than ever before. The integration
of structured and unstructured data, using natural lan-
guage processing and other sophisticated machine learn-
ing tools, is being tested and it is hoped this will lead to
a new level of integration of prior information with up-
to-date clinical information [44].
Over a thousand Mendelian disorders are linked to
genetic defects and, for many of these, genetic testing is
performed to inform clinical practice. The most suc-
cessful integration of basic and clinical data can be ob-
served in oncology [45, 46] and in research on rare
diseases [47–49]. However, the medical relevance of the
large amount of genetic variation revealed by genomic
sequencing is still unknown in most cases.
Data acquisition is undergoing rapid change. Wearable
devices, integrated sensors, and continuous monitoring
capabilities are available for all scales of measurements
[50]. Several legal issues will have to be tackled, for ex-
ample, when a consumer device becomes a diagnostic
device and the quality assurance and regulatory approval
are more stringent [51].
Data storage issues include security, accessibility, and
sustainability. Should data be stored centrally or in a fed-
erated manner? There are concerns about entrusting
health-related data to public clouds. As a result, there is
a strong need to come up with alternatives. The decades
of experience in big data management for the particle
physics community at The European Organization for
Nuclear Research (CERN) that led to the development
of the World Wide Web [52] will be valuable. However,
many aspects that are specific to big data in health re-
search need to be taken into account, such as data het-
erogeneity, institutional and legal fragmentation, and
strong data protection standards. There will be a massive
increase in big data production in all areas of biomed-
ical research, which includes studies at the preclinicallevels, such as animal or cellular models and transla-
tional studies, but also clinical research that involves
patients or public health research. To make the most
use of the information produced, several technical chal-
lenges should be addressed, such as the combination of
structured data, such as genotype, phenotype, and genom-
ics data, with semi-structured and unstructured data, e.g.,
medical imaging, EHRs, lifestyle, environmental, and
health economics data [53–56]. Recent successful exam-
ples show the feasibility of combining such data for trans-
lational and clinical research [57–59].
Technical challenges related to the management
of electronic health records
Adoption of EHRs across Europe varies greatly. Estonia
[60] and the Valencia Community in Spain (Josep Redón
i Màs, personal communication) have moved entirely to
EHRs. Integration is supported with auxiliary systems,
for instance drug–drug interaction alert systems that
warn physicians and pharmacists about potential pre-
scription clashes, clinical risk groups calculation and
costs (e.g., Valencia region, Spain), and drug–gene inter-
action alert systems that guide physicians to adjust the
dose of a prescribed drug in aberrant drug metabolizers
(e.g., The Netherlands). The USA have taken steps towards
a “patient-driven economy” [61]. In such a scenario, the
patient owns his/her data. This ownership requires the de-
velopment of an appropriate health-record infrastructure
but provides a wide range of new health service business
opportunities with major economic potential. Empowering
patients to take control of their data could be of particular
importance for cross-border healthcare and health re-
search activities in Europe where healthcare is highly frag-
mented and multinational. To transfer medical data from
one country to another in the EU is very difficult. Owner-
ship of data by patients could overcome these obstacles
and unleash new ways to stimulate a competitive health-
driven economy.
Furthermore, patient records can be computationally
opaque, for example, in the form of free text, recorded
speech, or medical images; translation into a format com-
patible with computational analyses will be necessary.
Data in different languages and time-consuming searches
and identification are other important barriers.
There are some best practices for the management of
EHRs. For example, the International Rare Diseases Re-
search Consortium (IRDiRC) [62] develops and implements
standards and harmonized methodology across diseases
and medical cases [63]. Several European collaborative
projects, such as the European project p-medicine, have
created IT infrastructures that will facilitate translational re-
search and the development of personalized medicine [64].
ELIXIR, one of the European infrastructures for life sci-
ences [65], has facilitated the collection, quality control, and
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translational medicine data [66].
Technical challenges related to data analysis and
computing infrastructures
Basic as well as clinical researchers need new computa-
tional tools to improve data access and aid user-friendly
data analysis for efficient decision making in the clinic. Cli-
nicians need new tools that track, trace, and provide fast
feedback for individual patient care. Researchers need tools
that can be adapted for different data sets and analyses
such as those used in a wide range of EU-funded projects
through the Innovative Medicines Initiative (IMI)-funded
eTRIKS consortium platform [67]. Accessing tool reposi-
tories to search for the best tool to answer specific research
or clinical questions will be a prerequisite. Equally import-
ant are traceable computational environments that
maintain data provenance information from patient to
sample and from sample to clinically actionable results.
In December 2012, the UK announced the 100,000 Ge-
nomes Project [68], which aims to sequence 100,000
genomes, from around 70,000 people, with the focus on
patients with rare diseases or cancer. The US and China
have recently announced plans for similar studies on
one million individuals. The goal of these projects is to
yield further insights into human health and disease
and to build a framework with which to integrate gen-
omics into standard public healthcare programs in the
near future. Data continue to increase at an exponential
rate and the need for cross-border exchange of biomed-
ical and healthcare data, cloud-storage, and cloud-
computing is inevitable [69, 70]. Until many issues of
data safety and security are solved, however, local solu-
tions will be favored [71].
Data quality, acquisition, curation, and
visualization
The quality and structure of health data available is incon-
sistent. A major challenge for preclinical and clinical re-
search is to obtain and achieve access to sufficient high
quality, informative data. Owing to a lack of harmonized
methods, in most cases health data cannot be directly
used for secondary purposes, such as quality of care, phar-
macovigilance, safety and efficacy of treatments, health
technology assessment, and public health policy. Efforts
are underway, in both Europe and the US, to develop and
implement standardized data collection, storage, and ana-
lysis [10, 72, 73]. The European Open Science Cloud, cre-
ated by the EC, will offer Europe’s 1.7 million researchers
and 70 million science and technology professionals a vir-
tual environment to store, share, and re-use their data
across disciplines and borders [74].
Data curation is often neglected but vitally important
to warrant high-quality, informative data [75]. Researchfunders need to make sure that sufficient attention is
paid to data quality at the experimental and study design
stages, for example, by ensuring data management plans
and appropriately reviewed data sharing procedures are
in place for all funded research.
“Seeing is believing”. This phrase is relevant not only for
high-resolution microscopy and imaging technologies but
also for the presentation and visualization of health-
related data. We need to progress from the current display
of “hairballs”, incomprehensible comprehensive networks,
or ranking tables that nobody has the time or motivation
to look at. If we want to provide clinicians with updated,
relevant information and clinical decision support sys-
tems, the devices have to be user-friendly and intuitive
with an interoperable format. The concept of disease-
specific maps, with a common computational framework,
might be one way to make progress, as demonstrated in
several EU-funded projects (Fig. 1).
Computational modeling and simulation
One of the pathways for exploitation of big data is its com-
bination with predictive, mechanistic models [76] such as
those provided by the European Molecular Biology La-
boratory–European Bioinformatics Institute (EMBL-EBI)
[77]. The Virtual Physiological Human (VPH) community
has also endeavored to develop a descriptive, integrative,
and predictive computational framework of human anat-
omy, physiology, and pathology with support from the EC
Directorate General for Communications Networks, Con-
tent & Technology (DG CONNECT) [78, 79], following
the path opened by the IUPS Physiome Project [80].
Predictive computational approaches are associated
with infrastructural challenges, particularly for the inte-
gration of data with analytical tools and workflows. On-
line environments such as VPH-Share and projects
such as p-medicine have appropriate infrastructures for
these applications [81].
Another approach to make sense of big data is based on
a systems-level understanding of health and disease [82].
Systems medicine integrative approaches are gradually
gaining visibility and enable translation of the human biol-
ogy complex and voluminous data into a toolbox to dem-
onstrate clinical impact [83]. However, a full appreciation
of the power of systems biology and computational
modeling for the upcoming changes in health re-
search and healthcare is still missing. Currently, with
the exception of oncology, there are still few highly
convincing use cases where systems biology ap-
proaches have found applications in routine clinical
care [45, 46, 84, 85]. Mathematical, computational dis-
ease models are unlikely to be routine in health re-
search anytime soon. Achieving necessary changes will
need strong support from funders to foster this para-
digm shift in methodology.
(a) (b) (c)
(d) (e) (f)
Fig. 1 Making sense of complex data and overcoming the hairball syndrome using systems biology algorithms and visualization tools. a Visualization of
the topology of clinical data from the U-BIOPRED consortium adult severe asthma cohorts (courtesy of Ratko Djukanovic, University of Southampton, UK
and Peter Sterk, Amsterdam Medical Center, The Netherlands) [126] using Topology Data Analysis from Ayasdi [127, 128]. b Network obtained though
integration of genome, transcriptome, and proteome data from the SysCLAD consortium lung transplantation cohorts (courtesy of Johann Pellet, EISBM,
France) [129, 130] using Ingenuity® Variant Analysis [131]. c Typical static representation of a molecular pathway in Thomson Reuters GeneGo MetaCore™
[132]. d An example of a detailed representation of biochemical reactions in the LCSB Parkinson’s molecular map [133]. e A cellular-level representation
of biological interactions in the EISBM AsthmaMap (courtesy of Alexander Mazein, EISBM, France) [134, 135]. f A network representation of data
and statements developed as part of a biocentric knowledge base within the eTRIKS consortium (courtesy of Mansoor Saqi and Irina Balaur,
EISBM, France) [67]
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A crucial aspect to be addressed concerns the regula-
tory acceptance of big data for the evaluation of novel
pharmacological or biological therapies to comple-
ment large randomized clinical trials [86]. Collabora-
tive pilot projects that test the use of big data in
observational and/or interventional large clinical trials
with the contribution of regulatory agencies can
bridge different methodological approaches and deter-
mine adapted quality standards. Universities and hos-
pitals do not have the procedures in place to
effectively capture and share data with other organi-
zations and countries. We need to develop and adopt
high quality standards for data generation and pro-
cessing to ensure that meaningful and valid data with
well-defined semantics are processed and shared. The
quality of data generation as well as the processing
and regulatory acceptance of big data are addressed
at the international level. Research initiatives such asthe International Cancer Genome Consortium (ICGC,
2016) [87], the International Human Epigenome Con-
sortium (IHEC, 2016) [88], the Genomic Standards
Consortium (GSC, 2016) [89], and the Clinical Data
Interchange Standards Consortium (CDISC) [90] and
by ISO standards committees (e.g., ISO TC276 WG5,
2016) provide some examples [91]. The recently pub-
lished FAIR Data Principles of Findability, Accessibil-
ity, Interoperability and Reusability for scientific data
management should help stakeholders from academia,
industry, funding agencies, and non-commercial pub-
lishers support the reuse of scholarly data [92]. Given
the complexity and high number of stakeholders in-
volved in the implementation of data standards within
hospital and university settings, the biggest chance for
success comes with highly focused pilot projects. Key fac-
tors include flexibility, expansion through modular strat-
egies, and the identification and involvement of key
healthcare actors providing them with immediate benefits.
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on clinical data interchange are also important. The Glo-
bal Alliance for Genomics and Health (GA4GH, 2016)
[93] initiative is working towards technical, ethical, and
legal frameworks to address and resolve some of these
issues. The Coordinated Research Infrastructures Build-
ing Enduring Life-science (CORBEL) Services, a recently
launched European consortium, will also contribute to
the above data-sharing challenges [94]. CORBEL is an
initiative of 11 new Biological and Medical Science Re-
search Infrastructures (BMS RIs), who together will cre-
ate a platform for harmonized user access to biological
and medical technologies, biological samples, and data
services (e.g., BRIDGEHEALTH consortium [95]). The
Genomics England policy [68] of storing all data within
the National Health Service (NHS) with highly regulated
restricted access to prevent abuse of private information
and user protocols might be a way to go forward. This
policy will need to be complemented by that of the UK
Personal Genome Project allowing volunteers to donate
their personal genome from Genomics England and
other sources to the public domain [96].
The processes and legal agreements for data sharing
across registries and European Member States are seldom
established. The harmonization of regulatory frameworks
is crucial while also ensuring personal data protection and
compliance with current legal frameworks, which includes
provisions on how to prevent, handle, and prosecute
potential abuse of the system. For example, there is no
consensus within international law on whether specific re-
quirements should be applicable to genetic information.
Several documents exist at the regional and international
levels that include useful guidelines, such as the UNESCO
International Declaration on Human Genetic Data (2003)
[97] and the Organisation for Economic Co-operation and
Development (OECD) Guidelines on Human Biobanks
and Genetic Research Databases (2009) [98]. The GA4GH
has developed the Framework for Responsible Sharing of
Genomic and Health-Related Data [99].
Privacy protection and data sharing policies
There are broad differences within and across Europe with
regards to privacy protection and data sharing polices
[100]. The workshop in Luxembourg emphasized that the
“one size fits all” approach will not be applicable in Europe.
The EC proposal for the General Data Protection Regula-
tion (2012/0011COD) [101] attempts to harmonize the
fragmented situation that exists under the current Data
Protection Directive (95/46/EC, European Parliament and
Council, 1995). In the compromise text concluded in the
trilogue negotiations between Parliament and the Council,
a paragraph is included in the preamble of the new act
which defines DNA and RNA as personal data [102]. A
Code of Practice on Secondary Use of Medical Data inEuropean Scientific Research Projects has been developed
[103] and is being deployed in the IMI-funded project
eTRIKS [67]. There is also a need to have a much higher
level of security than is possible today. One suggestion was
to explore block-chain technology, which makes use of a
digital, distributed transaction record, digital events, with
identical copies maintained on multiple computer systems,
shared between many different parties. Once entered, the
block-chain contains a certain and verifiable record of
every single transaction [104]. Originally used as the tech-
nology underlying “Bitcoin”, the potential to make secure
transactions of biomedical and healthcare data is being ex-
plored [105]. Another possibility would be to make use of
differentiated privacy approaches as practiced in health in-
formation exchanges [106].
Research infrastructures
Similarly, research infrastructures are instrumental to
support the harmonization of legal and ethical frame-
works in European countries, as demonstrated by the
Common Service on Ethical, Legal and Social Implica-
tions (CS ELSI) of Biobanking and BioMolecular re-
sources Research Infrastructure Consortium (CS ELSI
BBMRI-ERIC, 2016) [107]. The goal of ELSI BBMRI-ERIC
is to facilitate and support cross-border exchanges of hu-
man biological resources and data attached for research
uses, collaborations, and sharing of knowledge, experi-
ences, and best practices.
Existing computational infrastructures are coping with
storage of big data, but the challenge within the EU is the
lack of a large-scale European infrastructure and methods
of secure data distribution in a cross-border setting [108].
It is crucial to ensure that the infrastructures that exist
and evolve are coordinated and sustainable. Initiatives
such as ELIXIR [65] and the CS IT BBMRI-ERIC [109]
have begun to address these issues but there is a need for
coordination and significant strategic investments to
ensure that organizations such as these are equipped to
support the rapid growth and evolution of healthcare
informatics over the next decade. Distribution of ex-
pertise and facilities, consistent operation, and federation
throughout Europe are essential for scalability and long-
term sustainability. This has become one of the key chal-
lenges of distributed infrastructures such as BBMRI-ERIC
[110], ECRIN [111], and ELIXIR [65], which could benefit
from the long experience of CERN in particle physics as
discussed earlier [52].
Training and education: many health data,
insufficient health data scientists
One of the biggest bottlenecks and challenges is the avail-
ability of healthcare professionals and clinical researchers
that are able to use the latest information technologies de-
veloped in the big data analytics era [112, 113]. Data
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health application domain are rare. An equally important
bottleneck will be the lack of trained clinical scientists to
deal with big data. The majority of university hospitals
face a daily struggle to balance their budget. Clinical re-
search rarely brings in money to pay the costs for clinical
care. As a result, many university hospitals cease to main-
tain their culture of research as an essential basis for top-
level healthcare. Once the chain of training the next gen-
eration of clinical scientists is broken by the retirement of
the current trainers, the situation will change dramatically
and result in a catastrophic shift. Therefore, there is a
pressing need for programs that support the careers of
clinical scientists with state-of-the-art training in data ana-
lysis and management.
There is a clear lack of cross-disciplinary education
and training, which means that employees in the clinical
environment often do not have the expertise to deal with
big data in clinical research and healthcare. Coordinating
Action Systems Medicine (CASyM) [83] has developed
modules of multidisciplinary training for the next gener-
ation of researchers and medical doctors. Furthermore,
despite compulsory requirements of data transparency
applicable to clinical trials data, researchers and clini-
cians often have little incentive to make data fully avail-
able. Another challenge may be public skepticism about
the security of an integrated healthcare system. However,
several global initiatives have shown that individuals are
ready to share their medical data for advancing science
(Personal Genome Project) [96], which highlights the
potential contribution of citizen science to big data in
health research. Data donor cards would provide an in-
centive for people to make their data publicly available
and would work in the same way as organ donor cards,
thereby reusing a system already understood by many
people. Legislative approaches should include opt-in and
or opt-out solutions. For a successful transformation of
healthcare, we need to push the boundaries of interdisci-
plinarity, which comprises the natural sciences such as
biology and medicine, engineering, the social sciences,
and the humanities. Projects fail more often because of
the underappreciation of the complexities of ethical,
legal, and social factors than for technological reasons.
The workshop in Luxembourg brought together a
wide range of experts and stakeholders to discuss the
key developments, challenges, and potential solutions
that we face with using big data for the benefit of the
patients, the health care industry, and Europe as a
whole. The workshop resulted in specific recommenda-
tions for European policy-makers. There was no doubt
among the participants that big data and the revolution
in ICT will transform healthcare. There was also a
sense of urgency to implement rapidly the possible and
to tackle the yet impossible.Recommendations for an EU action plan
Launch pilot projects on the application of big data to
inform health
The primary recommendation is for the launch of pilot
projects on the application of big data that involve
healthcare providers, health technology developers,
policy-makers, and advisory bodies. Pilot translational
research projects that involve healthcare workers and
patients could bring big data closer to the clinic and
prove the value of collecting and analyzing such infor-
mation using the latest mathematical and computational
tools. The design principles for achieving integrated
healthcare information systems [114] might serve as guid-
ance on how small pilot projects can be used for future
expansion.
Leverage the potential of open and citizen science for the
exploitation of big data in health
The concept of “open science” includes open access to
publications and raw data, transparency of tools and meth-
odologies, and networking of researchers across fields and
countries [115]. Open science provides significant added
value in pilot studies and its broad implementation in the
scientific community and society is under discussion. For
example, a high-profile effort to switch all peer-reviewed
publishing to open access within the next years is envis-
aged [116–119].
The second recommendation is to encourage lever-
aging the complementarity between open and citizen
science in the context of big data in health. It will be im-
portant to inform and involve the public not only about
data collection but also about all aspects of health re-
search [120]. Consumer genomics companies are already
successful at gathering metadata through engagement
with their customers. The field of rare diseases has also
benefitted greatly from the involvement of parents of
children with such diseases, using non-traditional tech-
niques such as social media to build a network of related
cases of a particular syndrome. “Citizen science” is also
becoming increasingly important because of the in-
creased uptake of mobile health devices, consumer elec-
tronics, and household appliances and is well-aligned
with the EC focus on “responsible research and
innovation” that includes elements of open science in
its ongoing Horizon 2020 Framework Programme pol-
icy [121].
Catalyze the involvement of all relevant stakeholders in
projects
The third recommendation is to involve in projects all
relevant stakeholders, which includes clinicians, patient
organizations, researchers, software providers, healthcare
managers, ethical and legal experts, regulatory authorities,
policy-makers, pharmaceutical companies, and funding
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an effective translation from basic research to applied
healthcare and to bridge the organizational and cultural
differences in data sharing practices across Europe and
within the different health sectors in a worldwide context.
Clark and colleagues have laid out “a core set of lessons
that should become part of a basic training for researchers
interested in crafting usable knowledge for sustainable de-
velopment” [122]. One of the most important lessons is to
understand that research is a social and political process,
not just a process of discovery, and that stakeholders are
diverse and need to be involved in the team building
process at an early stage.
It is likely that bioinformaticians, biostatisticians, and
computational scientists will more often be included in the
near future as natural members of research and clinical
teams and healthcare administration, as already carried
out by global pharmaceutical organizations. Important to-
wards this direction is cross-disciplinary training and to
improve the dialogue between the information technology
experts, biologists, and clinicians, especially as these
groups have the potential to affect greatly the practical
outcome of research.
Support a rapid transition to new computational,
statistical, and other mathematical methods of analysis
The fourth recommendation is to foster the transition to
new computational, statistical, and other mathematical
methods of analysis that enable the integration of data
across the multiple scales of time and space typical of
complex biological systems in their healthy and diseased
states [123]: traditional methods of analysis are no lon-
ger scalable for such big data diversity. The roadmap de-
veloped by the Avicenna Coordination Support Action
provides a vision on how computer simulation will
transform the biomedical industry by developing “in
silico clinical trials” [124].
The need for new methods spans a wide range of
topics. We need effective methods for data integration,
collection, and data provenance management, for ex-
ample, the integration of genomics information and pa-
tient registries with EHRs and the integration of model
organism data into disease models. We also need im-
proved methodologies and tools to support data entry by
those recording data, such as visual and physiological
information. Innovative statistical methods, such as
models for predictive analytics and computational
models tailored to big data, are required to enable hy-
pothesis generation, estimation of risk models, and study
design. The Infrastructure, Design, Engineering, Archi-
tecture, and Integration project (IDeAl) [125] is taking
steps in this direction by developing new methods for
gene selection to tailor the design for small population
group trials. There may even be a requirement for newtypes of data and data formats. The development and
use of interoperable data, technology standards, and har-
monized operating procedures for data collection and
analysis are paramount to enable data integration and
to support data flow and federated access between pub-
lic and private partners. Furthermore, applicable data
protection standards and maintaining public trust are
important to realize the full potential of big data in
health research for European citizens and, by extension,
worldwide. In this regard, we need a definition of core
data sets that could serve as a common standard for
any individual health state.
Using the big data revolution to drive the transform-
ation of healthcare requires resources for state-of-the-art
ICT infrastructure, training programs, and pilot projects
that can serve as a role model. These costs, however, will
be overcompensated by the gains that will come with
the implementation of functioning digital workflows and
sophisticated health data analytics and the creation of a
new health and wellness industry.
Accelerate the harmonization of regulatory frameworks in
Europe for health-related research and data sharing
The final recommendation is to agree on the necessity for,
and the high priority of, accelerating the harmonization of
the European policy and regulatory frameworks that affect
health-related research and data sharing and the distribu-
tion of biological material used for the generation of data
necessary for research. There should be a balance between
the protection of an individual’s privacy, while acknow-
ledging that many patients are much more open about
data sharing than current policies seem to assume, and
the ability to proceed with research to ensure that Europe
remains competitive in health research. EU and national
funding bodies should take stock of the existing best prac-
tices and catalyze their adoption in transnational health
research.
Conclusions and future perspectives
The digital revolution is underway. A number of indus-
tries have already transformed their activities or have
now become inoperative. The driving forces are
miniaturization, automation, and now increasingly the
convergence of artificial intelligence, deep learning, and
robotics. Healthcare will not escape these developments.
In fact, big data as a driving force will play an even more
important role than in most industries. In Europe, work-
ing across borders is the only way to master the chal-
lenges of this scientific, technological, and industrial
revolution. The single most important factor is the
workforce. Countries that are ahead in ICT competence
and have an understanding of cultural differences and an
ability and willingness to work together have the best
chance to succeed.
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